293 related articles for article (PubMed ID: 26193663)
1. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.
Chen YJ; Wu H; Shen XZ
Cancer Lett; 2016 Sep; 379(2):245-52. PubMed ID: 26193663
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
3. The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma.
Yin J; Zhu JM; Shen XZ
Int J Cancer; 2015 Jan; 136(2):249-57. PubMed ID: 24420637
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma and the ubiquitin-proteasome system.
Dawson SP
Biochim Biophys Acta; 2008 Dec; 1782(12):775-84. PubMed ID: 18778769
[TBL] [Abstract][Full Text] [Related]
6. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
7. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
[TBL] [Abstract][Full Text] [Related]
8. Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-κB activity in hepatocellular carcinoma.
Zhang X; Lin C; Song J; Chen H; Chen X; Ren L; Zhou Z; Pan J; Yang Z; Bao W; Ke X; Yang J; Liang Y; Huang H; Tang D; Jiang L; Liu J
Cell Death Dis; 2019 Sep; 10(10):719. PubMed ID: 31558697
[TBL] [Abstract][Full Text] [Related]
9. Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.
Mansour MA; Aljoufi MA; Al-Hosaini K; Al-Rikabi AC; Nagi MN
Chem Biol Interact; 2014 May; 215():17-24. PubMed ID: 24632418
[TBL] [Abstract][Full Text] [Related]
10. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.
Lim JJ; Hooi L; Dan YY; Bonney GK; Zhou L; Chow PK; Chee CE; Toh TB; Chow EK
J Exp Clin Cancer Res; 2022 Aug; 41(1):249. PubMed ID: 35971164
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors: structure and function.
Nunes AT; Annunziata CM
Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
[TBL] [Abstract][Full Text] [Related]
12. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
14. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of microbial proteasome inhibitors.
Momose I; Kawada M
Int Immunopharmacol; 2016 Aug; 37():23-30. PubMed ID: 26589840
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways: translational potential of deubiquitinases as drug targets.
D'Arcy P; Linder S
Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788
[TBL] [Abstract][Full Text] [Related]
17. Proteasome deubiquitinases as novel targets for cancer therapy.
D'Arcy P; Linder S
Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
19. The immunoproteasome as a therapeutic target for hematological malignancies.
Miller Z; Lee W; Kim KB
Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
[TBL] [Abstract][Full Text] [Related]
20. The ubiquitin-proteasome-system.
Sommer T; Wolf DH
Biochim Biophys Acta; 2014 Jan; 1843(1):1. PubMed ID: 24055503
[No Abstract] [Full Text] [Related]
[Next] [New Search]